Clinical

Panelists discuss how biosimilar manufacturers offer both high-wholesale acquisition cost (WAC) and low-WAC product versions to navigate complex reimbursement landscapes, sharing their experiences with low-WAC options on formularies, defining private label agreements as strategies to improve biosimilar access across different patient populations, and examining the rationale behind PBMs' (pharmacy benefit managers) implementation of these agreements, including their specific components and benefits.

Panelists discuss how the significant price increases in reference biologics over the past decade have created market opportunities for biosimilars while exploring barriers to their adoption, potential solutions for enhancing uptake, and successful institutional strategies for increasing biosimilar utilization.

Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.

Despite holding promise in a range of disease states, a variety of challenges prevent cell and gene therapies (CGTs) from more widespread use, according to a new report from Cardinal Health.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

A higher composite dietary antioxidant index was found to decrease the chances of American adults developing cataracts.

Patients with HIV can take both their antiretroviral therapy (ART) and treatment to prevent tuberculosis safely to prevent infection and further spread of the virus.

Panelists discuss how airway clearance devices and techniques, including chest physical therapy, active cycle breathing, exercise, hypertonic saline, and oscillatory positive expiratory pressure devices, are the mainstay of bronchiectasis management.

Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR modulators for those with CF mutations or IgG supplementation.

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.

A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high tumors due to higher response rates when used earlier.

Stephen Speicher, MD, and Kate Estep, from Flatiron Health, discuss the future of oncology care with artificial intelligence (AI).

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.

Panelists discuss how treatment sequencing in immunoglobulin A (IgA) nephropathy will likely evolve toward a risk-stratified approach, beginning with optimized supportive care and renin-angiotensin system blockade, then incorporating targeted therapies based on specific disease mechanisms and biomarker profiles before resorting to broader immunosuppression.

A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve clinician awareness and adoption of molecular testing in community oncology settings while acknowledging that some effective treatments work across patient populations without requiring biomarker stratification.

Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).

Panelists discuss how emerging targeted therapies for immunoglobulin A (IgA) nephropathy address critical gaps in the current treatment landscape by offering disease-modifying potential, improved efficacy for resistant cases, and better safety profiles compared with traditional immunosuppression.

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).

As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.

Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.

New research links arthritis to an increased risk of prostate cancer, highlighting the need for further studies on prevention and treatment strategies.

Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.

Measles cases surge in the US as vaccination rates decline, raising concerns about outbreaks and public health under Robert F. Kennedy Jr's leadership.